UBS AM
TCRT icon

UBS AM’s Alaunos Therapeutics TCRT Stock Holding History

UBS AM’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,173
Closed -$115K – 2771
2022
Q1 		$115K Hold
1,173
– – ﹤0.01% 2730
2021
Q4 		$192K Sell
1,173
-680
-37% -$149K ﹤0.01% 2769
2021
Q3 		$506K Hold
1,853
– – ﹤0.01% 2498
2021
Q2 		$734K Buy
1,853
+334
+22% +$156K ﹤0.01% 2370
2021
Q1 		$820K Buy
1,519
+231
+18% +$144K ﹤0.01% 2178
2020
Q4 		$487K Hold
1,288
– – ﹤0.01% 2309
2020
Q3 		$487K Sell
1,288
-28
-2% -$12.4K ﹤0.01% 2155
2020
Q2 		$648K Buy
1,316
+260
+25% +$116K ﹤0.01% 2004
2020
Q1 		$388K Buy
1,056
+127
+14% +$65.7K ﹤0.01% 2070
2019
Q4 		$658K Buy
929
+284
+44% +$195K ﹤0.01% 2116
2019
Q3 		$414K Buy
645
+43
+7% +$34.1K ﹤0.01% 2361
2019
Q2 		$526K Sell
602
-79
-12% -$54.3K ﹤0.01% 2186
2019
Q1 		$393K Buy
681
+45
+7% +$18.8K ﹤0.01% 2204
2018
Q4 		$179K Buy
636
+186
+41% +$73.5K ﹤0.01% 2420
2018
Q3 		$216K Hold
450
– – ﹤0.01% 2412
2018
Q2 		$204K Sell
450
-77
-15% -$48.8K ﹤0.01% 2471
2018
Q1 		$310K Buy
527
+99
+23% +$61.7K ﹤0.01% 2195
2017
Q4 		$265K Buy
428
+59
+16% +$42.4K ﹤0.01% 2175
2017
Q3 		$340K Buy
369
+118
+47% +$105K ﹤0.01% 2041
2017
Q2 		$234K Hold
251
– – ﹤0.01% 2143
2017
Q1 		$239K Buy
251
+111
+79% +$103K ﹤0.01% 2098
2016
Q4 		$112K Sell
140
-231
-62% -$208K ﹤0.01% 2235
2016
Q3 		$313K Hold
371
– – ﹤0.01% 2244
2016
Q2 		$305K Sell
371
-99
-21% -$108K ﹤0.01% 2216
2016
Q1 		$523K Sell
470
-159
-25% -$163K ﹤0.01% 1898
2015
Q4 		$783K Buy
629
+278
+79% +$460K ﹤0.01% 1838
2015
Q3 		$475K Sell
351
-23
-6% -$38K ﹤0.01% 2046
2015
Q2 		$673K Buy
374
+90
+32% +$140K ﹤0.01% 1887
2015
Q1 		$459K Buy
284
+28
+11% +$41.5K ﹤0.01% 2020
2014
Q4 		$195K Hold
256
– – ﹤0.01% 2477
2014
Q3 		$101K Hold
256
– – ﹤0.01% 2513
2014
Q2 		$155K Hold
256
– – ﹤0.01% 2466
2014
Q1 		$176K Hold
256
– – ﹤0.01% 2451
2013
Q4 		$167K Buy
+256
New +$152K ﹤0.01% 2415

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS AM's TCRT Position: Q2 2022 in Review

UBS AM sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 1,173 shares — an estimated $115K sold.

UBS AM first reported a position in TCRT in Q4 2013 and held it in 34 quarters. The position peaked at $820K in Q1 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • UBS AM reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 1,173 Alaunos Therapeutics shares in Q2 2022, an estimated $115K.
  • UBS AM first reported a position in Alaunos Therapeutics in Q4 2013 and held it in 34 quarters.
  • UBS AM's Alaunos Therapeutics position peaked at $820K in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.